Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

AI Summary: In a dramatic showdown over obesity biotech firm Metsera, Pfizer’s up-to-$10B cash offer edged out Novo Nordisk’s bid. The fiercely competitive deal highlights the high stakes and intense market focus on innovative therapeutics in obesity management.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Pfizer vs Novo Nordisk in Battle for Metsera Takeover / 6 months

Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 7 wks

Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 2 months

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Biogen announces $5.6B acquisition of Apellis Pharma / 1 month

Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months